Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase 1 Study of LY2835219 In Participants With Advanced Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01394016
First received: July 12, 2011
Last updated: November 19, 2014
Last verified: November 2014

July 12, 2011
November 19, 2014
December 2009
April 2015   (final data collection date for primary outcome measure)
Number of participants with clinically significant effects (physical assessments and safety lab tests) [ Time Frame: Baseline through study completion (approximately 38 months) ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01394016 on ClinicalTrials.gov Archive Site
  • Number of participants with tumor response [ Time Frame: Baseline through study completion (approximately 38 months) ] [ Designated as safety issue: No ]
  • Pharmacokinetics, maximum plasma concentration (Cmax) [ Time Frame: Days -3, -2, -1, Days 1, 15, 22, 28 and 29 of Cycle 1 ] [ Designated as safety issue: No ]
  • Pharmacokinetics, area under the curve (AUC) [ Time Frame: Days -3, -2, -1, Days 1, 15, 22, 28 and 29 of Cycle 1 ] [ Designated as safety issue: No ]
  • Recommended dose for phase 2 studies [ Time Frame: Baseline to study completion (approximately 38 months) ] [ Designated as safety issue: No ]
  • Number of participants with tumor response [ Time Frame: Baseline through study completion (approximately 38 months) ] [ Designated as safety issue: No ]
  • Pharmacokinetics, maximum plasma concentration (Cmax) [ Time Frame: Days -3, -2, 1, Baseline, Days 1, 15, 28, and 29 of Cycle 1 ] [ Designated as safety issue: No ]
  • Pharmacokinetics, area under the curve (AUC) [ Time Frame: Days -3, -2, 1, Baseline, Days 1, 15, 28, and 29 of Cycle 1 ] [ Designated as safety issue: No ]
  • Recommended dose for phase 2 studies [ Time Frame: Baseline to study completion (approximately 38 months) ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
A Phase 1 Study of LY2835219 In Participants With Advanced Cancer
A Phase 1 Study of a CDK 4/6 Dual Inhibitor in Participants With Advanced Cancer

The purpose of this study is to determine a safe dose of LY2835219 to be given to participants with advanced cancer and to determine any side effects that may be associated with LY2835219 in this population. Efficacy measures will be used to assess the activity of LY2835219 in this population.

Not Provided
Interventional
Phase 1
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Advanced Cancer
  • Drug: LY2835219
    Administered orally, daily for 28-day cycles for two planned cycles. For Part G only in addition to LY2835219 as above, fulvestrant is administered as specified in the label. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
    Other Name: abemaciclib
  • Drug: Fulvestrant
    Fulvestrant is administered intramuscularly into the buttocks as specified in the label in Part G only.
Experimental: LY2835219
Interventions:
  • Drug: LY2835219
  • Drug: Fulvestrant
Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, Torres R, Ajamie RT, Wishart GN, Flack RS, Neubauer BL, Young J, Chan EM, Iversen P, Cronier D, Kreklau E, de Dios A. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014 Oct;32(5):825-37. doi: 10.1007/s10637-014-0120-7. Epub 2014 Jun 13.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
220
April 2015
April 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • For all Parts (Dose escalation and expansion): The participant must be, in the judgment of the investigator, an appropriate candidate for experimental therapy either after available standard therapies have ceased to provide clinical benefit (Parts A, B, C, D, E and F) or in combination with fulvestrant (Part G only)
  • For Dose Escalation (Part A): The participant must have histological or cytological evidence of cancer, either a solid tumor or a lymphoma, which is advanced and/or metastatic
  • For Dose Expansion (Parts B, C, D, E, F and G): The participant must have histological or cytological evidence of one of the following cancers:

    • Part B: Non-small cell lung cancer of any subtype that is advanced and/or metastatic
    • Part C: Glioblastoma multiforme that has progressed or recurred after radiotherapy and/or chemotherapy
    • Part D: Breast cancer that is advanced and/or metastatic
    • Part E: Melanoma that is advanced and/or metastatic
    • Part F: Colorectal Cancer
    • Part G: Breast Cancer that is not only advanced and/or metastatic but also hormone receptor positive
  • As defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) or the Revised Response Criteria for Malignant Lymphoma

    • For Parts A and G: Have measurable or nonmeasurable disease
    • For Parts B, C, D, E and F: Have measurable disease
  • Have given written informed consent prior to any study-specific procedures
  • Have adequate hematologic, hepatic, and renal function
  • Have a performance status less than or equal to 1 for Dose Escalation (Part A) and less than or equal to 2 for Dose Confirmation (Parts B, C, D, E, F and G) on the Eastern Cooperative Oncology Group (ECOG) scale
  • Have discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, and investigational therapy) with the exception of fulvestrant (for Part G only) for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug, and recovered from the acute effects of therapy (treatment related toxicity resolved to baseline) except for residual alopecia
  • Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
  • Males and females with reproductive potential must agree to use medically approved contraceptive precautions during the trial and for 3 months following the last dose of study drug
  • Females with child bearing potential must have a negative serum pregnancy test within 3 days of the first dose of study drug
  • Have an estimated life expectancy of greater than or equal to 12 weeks
  • Are able to swallow capsules

Exclusion Criteria:

  • Have received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of the initial dose of study drug for a nonmyelosuppressive or myelosuppressive agent, respectively
  • Have a personal history of any of the following conditions: presyncope or syncope of either unexplained or cardiovascular etiology, ventricular arrhythmia (including but not limited to ventricular tachycardia and ventricular fibrillation), sudden cardiac death or sudden cardiac arrest
  • Have serious preexisting medical conditions that, in the judgment of the investigator, would preclude participation in this study (for example, history of major surgical resection involving the stomach or small bowel)
  • For Dose Escalation (Part A): Have central nervous system (CNS) malignancy or metastasis
  • For Dose Confirmation (Parts B, D, E, F and G): Have CNS metastasis that is radiographically or clinically unstable less than 14 days prior to receiving study drug, regardless of whether they are receiving corticosteroids
  • For Dose Confirmation (Part C): Have glioblastoma multiforme that is radiographically or clinically unstable less than 14 days prior to receiving study drug, regardless of whether they are receiving corticosteroids
  • Have an acute leukemia
  • Have received an autologous or allogeneic stem-cell transplant within 75 days of the initial dose of study drug
  • Females who are pregnant or lactating
  • Have active bacterial, fungal, and/or known viral infection (for example, human immunodeficiency virus [HIV] antibodies, hepatitis B surface antigen [HBSAg], or hepatitis C antibodies) Screening is not required for enrollment
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01394016
13199, I3Y-MC-JPBA
No
Eli Lilly and Company
Eli Lilly and Company
Not Provided
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
November 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP